Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453158 | 1.00 | MAPT (0.57) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL29874096 | 0.86 | MAPT (0.61) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL23364477 | 0.86 | MAPT (0.61) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL23364541 | 0.83 | MAPT (0.58) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL29453124 | 0.81 | MAPT (0.54) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL27173183 | 0.80 | APP (0.55) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL30006266 | 0.80 | APP (0.55) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL26518067 | 0.80 | APP (0.57) | MAPTAPPSNCA | |
| SCHEMBL30007101 | 0.79 | PAX8 (0.44) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL30828341 | 0.77 | APP (0.53) | MAPTKDM4ENPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-08-25 | — | — | US | disclosed |
| WO-2021097243-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPT 1/4885KDM4E 3871/4885NPC1 417/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPT 1/4885KDM4E 3871/4885NPC1 417/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | MAPT 1/4885KDM4E 3871/4885NPC1 417/4885 |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | MAPT 1/4885KDM4E 3835/4885NPC1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.